Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aurobindo Pharma Ltd.

www.aurobindo.com

Latest From Aurobindo Pharma Ltd.

FDA 2017 First Generics Approvals Retain India Imprint

Indian companies continued to have marked presence in list of first generics approved by US FDA in 2017; clearances include some limited competition drugs and complex products that are vital for Indian firms as they transition their portfolios away from 'plain vanilla' generics.

Approvals FDA

Private Label Nexium OTC Buoys Perrigo As Pricing Trims Rx Revenues

Perrigo's third-quarter launch of private label Nexium24HR was primary contributor of $13m in new product sales in North America.

Consumer Consumer

Cipla Primes For US Momentum But Seretide Generic Is Slow In UK

Cipla reported a strong second quarter, with management upbeat about building momentum in the US business with a “good mix” of differentiated launches. The ramp-up of the firm’s Seretide generic in the UK, though, appears slow.

Generic Drugs Strategy

Decision Against Attorney Fees In Mucinex Patent Claim Could Resonate

US federal court judge says Mucinex marketer Reckitt Benckiser is not responsible for OTC private label competitor Aurobindo’s attorney fees because its patent infringement complaint was not “exceptional” and its argument had merit. The decision could bolster drug firms' confidence in defending their patents.

Consumer Legal Issues
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • India
  • Parent & Subsidiaries
  • Aurobindo Pharma Ltd.
  • Senior Management
  • N Govindarajan, Mng. Dir.
  • Contact Info
  • Aurobindo Pharma Ltd.
    Phone: (91) 40 6672 5000
    WaterMark Bldg., Level 1
    Plot #11,Surv#9
    Hyderabad, 500 084
    India
Advertisement
Advertisement
UsernamePublicRestriction

Register